Histological characterization and pharmacological, control of chronic rejection in xenogeneic and allogeneic heart transplantation

Transplantation

Volumn 66, Issue 6, 1998, Pages 692-698

  Shen, Jikun ^a   Chong, Anita S F ^a   Xiao, Fei ^a   Liu, Wei ^a   Huang, Wanyun ^a   Blinder, Leonard ^a   Foster, Preston ^a   Sankary, Howard ^a   Jensik, Stephen ^a   Mcchesney, Lawrence ^a   Mital, Deepak ^a   Williams, James W ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; LEFLUNOMIDE;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTERY INTIMA PROLIFERATION; ARTICLE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; IMMUNOGLOBULIN DEPOSITION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY INFILTRATE; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTIC INFILTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYRIAN HAMSTER; XENOTRANSPLANTATION;

ANIMALS; CHRONIC DISEASE; CRICETINAE; CYCLOSPORINE; DISEASE MODELS, ANIMAL; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MALE; MESOCRICETUS; MYOCARDIUM; RATS; RATS, INBRED F344; RATS, INBRED LEW; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032572983     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199809270-00002     Document Type: Article

References (23)

1. Cecka JM. Outcomes statistics of renal transplants with an emphasis on long-term survival. Clin Transplant 1995; 8: 324.
2. Billingham ME, Cary NRB, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection. J Heart Transplantation 1990; 9: 587
3. Xiao F, Chong A, Foster P, et al. Leflunomide controls rejection in hamster to rat cardiac xenografts. Transplantation 1994; 58: 828.
4. Lin Y, Vandepute M, Waer M. Effect of leflunomide and cyclosporine on the occurrence of chronic xenograft lesions. Kidney Int 1995; 48: 23.
5. Xiao F, Shen J, Chong A, et al. Control and reversal of chronic rejection in hamster to rat cardiac transplantation. Transplant Proc 1996; 28: 691.
6. Adams DH, Tilney NL, Collins JJ, Karnovsky M. Experimental graft arteriosclerosis. I. The Lewis to F-344 allograft model. Transplantation 1992; 53: 1115.
7. Xiao F, Chong A, Shen J, et al. Pharmacologically induced regression of chronic transplant rejection. Transplantation 1995; 60: 1065.
8. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thoracic Cardiovasc Surg 1969; 57: 225.
9. Billingham ME. Pathology and etiology of chronic rejection of the heart. Clin Transplant 1994; 8: 289.
10. Foegh ML. Chronic rejection-graft arteriosclerosis. Transplant Proc 1990; 22: 119
11. Ferguson R. Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant 1994; 8: 328.
12. Narrod J, Kormos R, Armitage J, Hardesty R, Ladowski J, Griffith B. Acute rejection and coronary artery disease in long-term survivors of heart transplantation. J Heart Transplantation 1989; 8: 418.
13. Williams JW, Xiao F, Foster P, et al. Leflunomide in experimental transplantation: control of rejection and alloantibody production, reversal of acute rejection with cyclosporine. Transplantation 1994; 57: 1223.
14. Kuchle CCA, Thoenes GH, Langer KH, Schorlemmer HU, Bartlett RR, Schleyerbach R. Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent. Transplant Proc 990; 23:1803.
15. Schorlemmer HU, Seiler FR, Bartlett RR. Prolongation of allogeneic transplanted skin grafts by leflunomide (HWA 486), a nw immunosuppressive isoxazole derivative. Transplant Proc 1993; 25: 763.
16. Foster PF, Xiao F, Kociss K, et al. Leflunomide immunosuppression in rat small intestinal transplantation. Transplant Proc 1994, 26: 1599.
17. McChesney L, Xiao F, Sankary HN, et al. Evaluation of leflunomide in the canine renal transplantation model. Transplantation 1994; 57: 1717.
18. Morris RE, Huang X, Cao W, Zheng B, Shorthouse RA. Leflunomide (HWA 486) and its analog suppress T- and B-cell proliferation in vitro, acute rejection, ongoing rejection and antidonor antibody synthesis in mouse, rat and cynomolgus monkey transplant recipients as well as arterial intimai thickening after balloon catheter injury. Transplant Proc 1995; 27: 445.
19. Swan SK, Crary GS, Guijarro C, O'Donnell MP, Keane WF, Kasiske BL. Immunosuppressive effects of leflunomide in experimental chronic vascular rejection. Transplantation 1995; 60: 887.
20. Nair RV, Cao W, Morris RE. Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine. Immunol Lett 1995; 47: 171.
21. Chong A, Shen J, Xiao F, et al. Delayed xenograft rejection in the concordant hamster heart into Lewis rat model. Transplantation 1996; 58: 828.
22. Chong ASF, Ma L, Shen J, Blinder L, Yin DP, Williams JW. Modification of humoral responses by the combination of leflunomide and cyclosporine. Transplantation 1997; 64: 1650.
23. Lin Y, Vandeputte M, Waer M. Accommodation and T-independent B cell tolerance in rats with long term surviving hamster heart xenografts. J Immunol 1997; 160: 369